Prognia
Drug Database
🇪🇺EU · EMAWithdrawnATC: J04AA01

Granupas (previously Para-aminosalicylic acid Lucane)(para-aminosalicylic acid)

Tuberculosis

Marketing Authorisation Holder: Eurocept International B. V.

EMA Authorisation: 07/04/2014

INN: para-aminosalicylic acid

Indication

Granupas is indicated for use as part of an appropriate combination regimen for multi-drug resistant tuberculosis in adults and paediatric patients from 28 days of age and older when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability (see section 4.4). Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Granupas (previously Para-aminosalicylic acid Lucane) — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.